A therapeutic human antibody against the domain 4 of the Bacillus anthracis protective antigen shows protective efficacy in a mouse model

2019 ◽  
Vol 509 (2) ◽  
pp. 611-616
Author(s):  
Bo-Eun Ahn ◽  
Hee-Won Bae ◽  
Hae-Ri Lee ◽  
Sun-Je Woo ◽  
Ok-Kyu Park ◽  
...  
Keyword(s):  
Mouse Model ◽  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Protective Efficacy ◽  
Human Antibody ◽  
Domain 4

scholarly journals A Recombinant Carboxy-Terminal Domain of the Protective Antigen of Bacillus anthracis Protects Mice against Anthrax Infection

2002 ◽  
Vol 70 (3) ◽  
pp. 1653-1656 ◽  
Author(s):  
Helen C. Flick-Smith ◽  
Nicola J. Walker ◽  
Paula Gibson ◽  
Helen Bullifent ◽  
Sarah Hayward ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Fusion Proteins ◽  
Protective Antigen ◽  
Protective Efficacy ◽  
Terminal Domain ◽  
Carboxy Terminal Domain ◽  
Anthrax Infection ◽  
Carboxy Terminal ◽  
Domain 4

ABSTRACT The immunogenicity and protective efficacy of overlapping regions of the protective antigen (PA) polypeptide, cloned and expressed as glutathione S-transferase fusion proteins, have been assessed. Results show that protection can be attributed to individual domains and imply that it is domain 4 which contains the dominant protective epitopes of PA.

Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model

2014 ◽  
Vol 59 (1) ◽  
pp. 91-99 ◽  
Author(s):  
Shivakiran S. Makam ◽  
Joseph J. Kingston ◽  
Murali S. Harischandra ◽  
Harsh V. Batra
Keyword(s):  
Mouse Model ◽  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Chimeric Protein

scholarly journals Vaccination against Anthrax with Attenuated Recombinant Strains of Bacillus anthracis That Produce Protective Antigen

1999 ◽  
Vol 67 (2) ◽  
pp. 562-567 ◽  
Author(s):  
John P. Barnard ◽  
Arthur M. Friedlander
Keyword(s):  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Plasmid Stability ◽  
Protective Efficacy ◽  
Live Vaccines ◽  
Antibody Titers ◽  
Anthrax Protective Antigen ◽  
Anthrax Vaccines

ABSTRACT The protective efficacy of several live, recombinant anthrax vaccines given in a single-dose regimen was assessed with Hartley guinea pigs. These live vaccines were created by transforming ΔANR and ΔSterne, two nonencapsulated, nontoxinogenic strains of Bacillus anthracis, with four different recombinant plasmids that express the anthrax protective antigen (PA) protein to various degrees. This enabled us to assess the effect of the chromosomal background of the strain, as well as the amount of PA produced, on protective efficacy. There were no significant strain-related effects on PA production in vitro, plasmid stability in vivo, survival of the immunizing strain in the host, or protective efficacy of the immunizing infection. The protective efficacy of the live, recombinant anthrax vaccine strains correlated with the anti-PA antibody titers they elicited in vivo and the level of PA they produced in vitro.

scholarly journals Protective antigen domain 4 of Bacillus anthracis as a candidate for use as vaccine for anthrax

2019 ◽  
Vol 26 (3) ◽  
pp. 392-395 ◽  
Author(s):  
Dorota Żakowska ◽  
Grzegorz Graniak ◽  
Paweł Rutyna ◽  
Katarzyna Naylor ◽  
Patrycja Głowacka ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Domain 4

scholarly journals Oral Administration of a Salmonella enterica-Based Vaccine Expressing Bacillus anthracis Protective Antigen Confers Protection against Aerosolized B. anthracis

2006 ◽  
Vol 75 (4) ◽  
pp. 1827-1834 ◽  
Author(s):  
Margaret G. M. Stokes ◽  
Richard W. Titball ◽  
Brendan N. Neeson ◽  
James E. Galen ◽  
Nicola J. Walker ◽  
...  
Keyword(s):  
Bacillus Anthracis ◽  
Salmonella Enterica ◽  
Protective Antigen ◽  
Oral Immunization ◽  
Full Length ◽  
Serovar Typhimurium ◽  
First Time ◽  
Pa Domain ◽  
Human Vaccine ◽  
Domain 4

ABSTRACTBacillus anthracisis the causative agent of anthrax, a disease that affects wildlife, livestock, and humans. Protection against anthrax is primarily afforded by immunity to theB. anthracisprotective antigen (PA), particularly PA domains 4 and 1. To further the development of an orally delivered human vaccine for mass vaccination against anthrax, we producedSalmonella entericaserovar Typhimurium expressing full-length PA, PA domains 1 and 4, or PA domain 4 using codon-optimized PA DNA fused to theS. entericaserovar Typhi ClyA and under the control of theompCpromoter. Oral immunization of A/J mice withSalmonellaexpressing full-length PA protected five of six mice against a challenge with 105CFU of aerosolizedB. anthracisSTI spores, whereasSalmonellaexpressing PA domains 1 and 4 provided only 25% protection (two of eight mice), andSalmonellaexpressing PA domain 4 or aSalmonella-only control afforded no measurable protection. However, a purified recombinant fusion protein of domains 1 and 4 provided 100% protection, and purified recombinant 4 provided protection in three of eight immunized mice. Thus, we demonstrate for the first time the efficacy of an oralS. enterica-based vaccine against aerosolizedB. anthracisspores.

scholarly journals A Single-Dose PLGA Encapsulated Protective Antigen Domain 4 Nanoformulation Protects Mice against Bacillus anthracis Spore Challenge

PLoS ONE ◽  
2013 ◽  
Vol 8 (4) ◽  
pp. e61885 ◽  
Author(s):  
Manish Manish ◽  
Amit Rahi ◽  
Manpreet Kaur ◽  
Rakesh Bhatnagar ◽  
Samer Singh
Keyword(s):  
Single Dose ◽  
Bacillus Anthracis ◽  
Protective Antigen ◽  
Domain 4
Sign in / Sign up

Export Citation Format

Share Document